Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer

Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) greatly benefit from EGFR-tyrosine kinase inhibitors (EGFR-TKIs) while the prognosis of patients who lack EGFR-sensitive mutations (EGFR wild type, EGFR-WT) remains poor due to a lack of effective therapeutic strategies. There is an urgent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Wang, Yizhe, Zheng, Chunlei, Lu, Wenqing, Wang, Duo, Cheng, Yang, Chen, Yang, Hou, Kezuo, Qi, Jianfei, Liu, Yunpeng, Che, Xiaofang, Hu, Xuejun
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7982742/
https://ncbi.nlm.nih.gov/pubmed/33763356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.620154
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados